Ratio Therapeutics, a Boston, MA-based pharmaceutical company, raised $50M in Series B funding.
The round, which brought the total amount to $90M, was led by Schusterman and Duquesne and others such as PagsGroup, Bristol Myers Squibb and the Center for Technology Licensing at Cornell University.
The company intends to use the funds to expand the applications of its proprietary technology platforms, Trillium™ and Macropa™, to develop novel best in class fit-for-purpose radiopharmaceuticals.
Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., Ratio Therapeutics is a pharmaceutical company with the mission to accelerate the development of precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. It company currently employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. Its proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery, and advancement of novel radiopharmaceuticals.
Ratio currently collaborates with Bayer, Lantheus and Merck.
FinSMEs
19/01/2024